Saturday 17 October 2026
Export CLVSQ’s income statement to Excel — free account
Clovis Oncology, Inc.
CLVSQ Healthcare Biotechnology
Operating cash flow growth for five consecutive years.
Follow CLVSQ
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | Trend | 2022e | 2023e | 2024e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2022–2024 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 278 | 360 | 468 | 484 | 429 | 413 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.15 | 0.20 | 0.30 | 0.38 | 0.36 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 56 | 95 | 143 | 165 | 149 | ||||
| Gross margin, % | — | — | — | — | 10.26 | 78.86 | 76.86 | 75.75 | 74.89 | 73.90 | |||||
| EBT | — | — | — | — | (381) | (350) | (367) | (399) | (370) | (265) | |||||
| EBT margin, % | — | — | — | — | (488,680.77) | (630.46) | (385.16) | (278.75) | (224.75) | (178.09) | |||||
| Net income | — | — | — | — | (349) | (346) | (368) | (400) | (369) | (265) | |||||
| Depreciation | — | — | — | — | 107 | 4 | 8 | 9 | 11 | 11 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 1.18 | 1.83 | 2.65 | 1.95 | 1.29 | ||||
| Earnings | — | — | — | — | (9.07) | (7.36) | (7.07) | (7.43) | (4.38) | (2.29) | |||||
| Cash flow | — | — | — | — | (6.93) | (5.55) | (7.03) | (6.01) | (3.00) | (1.70) | |||||
| Capex | — | — | — | — | (0.02) | (0.09) | (1.23) | (0.35) | (0.10) | 0.00 | |||||
| Free cash flow | — | — | — | — | (6.95) | (5.63) | (8.26) | (6.36) | (3.10) | (1.70) | |||||
| Book value | — | — | — | — | (0.09) | 7.81 | 2.81 | (3.23) | (1.88) | (2.41) | |||||
| Shares, m | — | — | — | — | 38 | 47 | 52 | 54 | 84 | 116 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 0.00 | 55.98 | 9.80 | 3.93 | 2.46 | 2.10 | |||||
| P/B | — | — | — | — | 0.00 | 8.45 | 6.38 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | 0.00 | 50.91 | 10.38 | 6.65 | 4.71 | 5.30 | |||||
| EV/FCF | — | — | — | — | (6.24) | (10.66) | (2.30) | (2.78) | (2.97) | (3.86) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (267) | (261) | (366) | (324) | (253) | (196) | ||||
| Capex | — | — | — | — | (1) | (4) | (64) | (19) | (8) | 0 | |||||
| Free cash flow | — | — | — | — | (267) | (265) | (430) | (342) | (261) | (196) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 214 | 545 | 447 | 233 | 126 | 73 | ||||
| Total debt | — | — | — | — | 281 | 304 | 577 | 685 | 610 | 607 | |||||
| Net debt | — | — | — | — | 15 | (259) | 56 | 388 | 370 | 463 | |||||
| Shareholders’ equity | — | — | — | — | (4) | 368 | 146 | (174) | (159) | (279) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (64.78) | (62.99) | (46.04) | (52.23) | (57.91) | (49.06) | ||||
| ROIC | — | — | — | — | (2,059.94) | (137.10) | (102.86) | (109.91) | (89.52) | (76.50) | |||||
| ROE | — | — | — | — | (235.10) | (190.33) | (143.16) | 2,881.99 | 221.75 | 120.90 | |||||
Negative figures in brackets.
Fiscal years to Dec 2021 · latest quarter Sep 2022
Charts ten years each
Clovis Oncology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DARE Dare Bioscience, Inc. | $14.6M | — (loss-making) | — (loss-making) | +984.43% (above 0%: growing) | n/m | −30.23% (below 0%: shrinking) | (70.56%) | (1,582.93%) | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | — (loss-making) | — (loss-making) | −89.33% (below 0%: shrinking) | n/m | −174.72% (below 0%: shrinking) | 81.71% | (221.45%) | Compare |
| CNSY Cerenome, Inc. | $14.3M | — (loss-making) | — (loss-making) | −70.43% (below 0%: shrinking) | n/m | −31.46% (below 0%: shrinking) | 100.00% | (2,203.65%) | Compare |
| TVRD Tvardi Therapeutics, Inc. | $14.3M | — (loss-making) | — (loss-making) | +20.33% (above 0%: growing) | n/m | −57.26% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLVSQ Clovis Oncology, Inc. | $14.2M | — (loss-making) | — (loss-making) | −19.13% (below 0%: shrinking) | n/m | +11.83% (above 0%: growing) | 71.93% | (144.26%) | |
| BCDA BioCardia, Inc. | $14.2M | — (loss-making) | — (loss-making) | −93.02% (below 0%: shrinking) | n/m | −5.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RVLP RVL Pharmaceuticals PLC | $14.1M | — (loss-making) | — (loss-making) | −2.25% (below 0%: shrinking) | n/m | −734.24% (below 0%: shrinking) | 76.43% | (266.66%) | Compare |
| LPCN Lipocine Inc. | $13.9M | — (loss-making) | — (loss-making) | −69.48% (below 0%: shrinking) | n/m | −60.56% (below 0%: shrinking) | 100.00% | (1,495.11%) | Compare |
| KTTA Pasithea Therapeutics Corp. | $13.7M | — (loss-making) | — (loss-making) | +1,494.04% (above 0%: growing) | n/m | −21.68% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $14.2M | — | — | −35.86% | — | −44.36% | 90.86% | (244.05%) |
Clovis Oncology, Inc. (CLVSQ) Latest News
No news at this impact. Lower the threshold for more.